Home Package Inserts -Antibody-drug Conjugates

Package Inserts -Antibody-drug Conjugates

U.S. Food and Drug Adminstration Approved and Commercially available Antibody-drug Conjugates (ADC)

Antibody-drug Conjugates

This page lists antibody-drug conjugates (ADCs) approved by the United States Food and Drug Administration (FDA).

 Year Approved**
Drug (INN)*Trade NameDeveloperFDA
Gemtuzumab OzogamicinMaylotarg®Wyeth/Pfizer2000
(Witdrawn)
Gemtuzumab OzogamicinMaylotarg®Wyeth/Pfizer2017 (Reintroduced)
Brentuximab VedodinAdcetris®Seattle Genetics /Takeda2011
Ado-trastuzumab emtansineKadcyla®Genentech /Roche2013
Inotuzumab OzogamicinBesponsa®Wyeth /Pfizer2017
Polatuzumab vedotin-piiqPolivy™Genentech /Roche2019
Enfortumab Vedotin-ejfvPadcev™Astellas /Seattle Genetics2019
Fam-trastuzumab deruxtecan-nxkiEnhertu®Daiichi Sankyo /AstraZeneca2019
Belantamab mafodotin-blmfBlenrep™GSK /GlaxoSmithKline2020
Sacituzumab govitecan-hziyTrodelvy™Gilead /Immunomedics2020
    
    

* Link to drug description ** Link to package insert

Additional Resources

ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X